文献速递泌尿男性生殖肿瘤

多基因风险评分与接受主动监测的前列腺癌患者分级升级的关系

Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项前瞻性多中心队列研究纳入1220例接受主动监测的临床局限性前列腺癌患者,随访中位5.3年,发现多基因风险评分(PRS-451和PRS-400)每增加1个标准差与分级升级风险升高相关,PRS-400还与更小的前列腺体积、更高的活检穿刺阳性针数比例和更高的PSA密度相关;在临床风险因素模型中加入PRS-400后C-index由0.64升至0.65。

要点

  • 多基因风险评分(PRS-451和PRS-400)每增加1个标准差与分级升级风险升高相关。
  • PRS-400与更小的前列腺体积、更高的活检穿刺阳性针数比例和更高的PSA密度相关。
  • 在临床风险因素模型中加入PRS-400后C-index由0.64升至0.65。

核心结论

  • 在接受主动监测的患者中,高多基因风险评分与分级升级风险相关,并可能与肿瘤多灶性相关。
  • 从PRS中排除PSA相关变异后,显示与更小的前列腺体积相关,而更小的前列腺体积既往与更具侵袭性的肿瘤相关。
  • 尽管PRS可能为主动监测提供信息,但其是否改善临床决策尚待观察。

研究设计与样本

  • 这项前瞻性多中心队列研究纳入来自美国10个中心的Canary前列腺主动监测研究(PASS)的1220例临床局限性(cT1-T2)前列腺癌接受主动监测的患者,入组时间为2008年7月至2017年11月,随访至2022年8月,中位随访5.3年。
  • 暴露为451个前列腺癌风险变异的多祖先PRS(PRS-451)和排除PSA相关变异后的400个前列腺癌风险变异PRS(PRS-400)。
  • 分析时间为2023年1月至2024年4月。

主要发现

  • 1220例接受主动监测的患者诊断时中位(IQR)年龄为63(58-67)岁;随访期间470例发生分级升级,2年和5年分级升级风险分别为17.7%(95%CI,15.5%-19.9%)和33.3%(95%CI,30.5%-36.3%)。
  • 随访期间任意时间点,PRS-451每增加1个标准差与分级升级风险增加23%相关(95%CI,1.11-1.35;P < .001),PRS-400与分级升级风险增加27%相关(95%CI,1.15-1.39;P < .001)。
  • 除PSA外,PRS-400与其余结局的关联相似或更强;较高的PRS-400与更小的前列腺体积、更高的活检穿刺阳性针数比例和更高的PSA密度相关。
  • 包含临床风险因素的模型C-index为0.64(95%CI,0.62-0.67);加入PRS-400后C-index为0.65(95%CI,0.63-0.68)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Active surveillance is the preferred management strategy for patients with low- or favorable intermediate-risk prostate cancer (PCa); however, frequent health care visits can be costly and burdensome to patients. Identifying patients who may benefit from intensive vs passive surveillance could reduce these burdens. OBJECTIVE: To investigate associations between a polygenic risk score (PRS) and risk of upgrading and other prostate tumor features in patients receiving active surveillance. DESIGN, SETTING, AND PARTICIPANTS: This prospective multicenter cohort study across 10 US sites included 1220 patients from the Canary Prostate Active Surveillance Study (PASS) enrolled from July 2008 to November 2017, with follow-up (median, 5.3 years) through August 2022. Participants were those with clinically localized PCa (cT1-T2) receiving active surveillance. Analyses took place from January 2023 to April 2024. EXPOSURE: Multi-ancestry PRS of 451 PCa risk variants (PRS-451) and 400 PCa risk variants (PRS-400) after excluding prostate-specific antigen (PSA)-associated variants. MAIN OUTCOMES AND MEASURES: The primary outcome was PCa upgrading (any Gleason grade increase) vs no upgrading. Secondary outcomes included prostate volume, PSA, PSA density, percentage of biopsy cores with cancer, and Gleason grade group at diagnosis. RESULTS: The median (IQR) age at diagnosis of the 1220 patients receiving active surveillance was 63 (58-67) years. During follow-up, 470 patients upgraded; the 2- and 5-year risks of upgrading were 17.7% (95% CI, 15.5%-19.9%) and 33.3% (95% CI, 30.5%-36.3%), respectively. Each 1-SD unit increase in PRS-451 was associated with 23% increased hazard of upgrading (95% CI, 1.11-1.35; P < .001), whereas PRS-400 was associated with 27% increased hazard (95% CI, 1.15-1.39; P < .001) at any point in time during follow-up. Except for PSA, associations with remaining outcomes were similar or stronger using PRS-400. Higher PRS-400 was associated with smaller prostate volume, a higher percentage of biopsy cores with cancer, and higher PSA density. A model with clinical risk factors had a C-index of 0.64 (95% CI, 0.62-0.67); adding PRS-400 led to a C-index of 0.65 (95% CI, 0.63-0.68). CONCLUSIONS AND RELEVANCE: In this cohort study, among patients receiving active surveillance, high PRS was associated with risk of upgrading and possibly tumor multifocality. Excluding PSA variants from the PRS revealed an association with smaller prostate size, which has been previously associated with more aggressive tumors. Although PRS may inform active surveillance, it is yet to be seen whether they improve clinical decisions.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Goss LB, Liu M, Zheng Y, et al. Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance. JAMA Oncol. 2025. PMID: 39666350. doi:10.1001/jamaoncol.2024.5398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。